More on TCRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.13 |
|
|||
| Open | $1.14 | ||||
| 52 Wk High | $26.80 | ||||
| 52 Wk Low | $23.00 | ||||
| Day High | $1.16 | ||||
| Day Low | $1.06 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 716,501 | ||||
- TScan Therapeutics, Inc. (TCRX) Tops Q4 EPS by 9c
- Form S-8 TScan Therapeutics, Inc.
- Form 10-K TScan Therapeutics, Inc. For: Dec 31
- Form 8-K TScan Therapeutics, Inc. For: Mar 04
- TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- TScan completes enrollment in phase 1 trial, receives FDA clearance for two new drug candidates
- TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
- TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
- Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: Amello Jason
- Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: MacBeath Gavin
Entities mentioned with TCRX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Morgan Stanley | View Related Stories »
- S3 | View Related Stories »
- Cowen & Co | View Related Stories »
- IPO | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
